Freeze-dried Powder Retatrutide Weight Loss Semaglutide High Purity raw material
COA 2 Inquiries
143045-27-6
Pharmaceutical Grade
99%
ningbo
peijia
0.1mg 1mg per vial;10vials/box
2026-08-20
peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificatesBasic Info
-
Product Name:
LONG R3 IGF-I RECOMBINANT ANALOG
Other Name:LONG R3 IGF-I RECOMBINANT ANALOG;long R3 igf-I;LONGR3IGF-I MEDIA GRADE;LONG? R3 IGF-I human;rh-IGF-1;LONG R3 IGF-1 (human)
CAS No.:143045-27-6
Molecular Weight:0
Categories:
Characteristics-
Critical Temperature & Pressure:
2-8°C
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptide
-
Location:
Hangzhou Peijia E-commerce Co., LTD
-
Year of Establishment:
2026
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
United States
igf1 lr3
1 G Jun 4, 2026
Australia
IGF-lr3
100 Dec 22, 2023 Post an enquiry for this product